Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

Authors

• Sun Min Lim
• Jiunn-Liang Tan
• Josiane Mourao Dias
• Pei Jye Voon
• Soon Hin How
• Xiangdong Zhou
• Hailin Xiong
• Bartomeu Massuti
• Louise C. Medley
• Misako Nagasaka
• David Vicente
• Nicolas Girard
• Achim Rittmeyer
• Dana-Adriana Botesteanu
• Ali Alhadab
• Janine M. Mahoney
• Jie Zhang
• Joshua Michael Bauml
• Mahadi Baig
• Susan Combs Scott

Document Type

Article

Publication Date

6-1-2024

Abstract

[no abstract]

Keywords

283-197-481, 261-492-3532-2373, 613-3267-3650-3634-10059, 613-135-4642-282-153-924, 283-197-481, 613-225-2575-3984, 613-225-325, 613-225-2782, 6, 6, 3, 3, 3, 3, 3, 2, 4310, 3340, 194, 4310, 3340, 3, 3, 1, 1, 1

Publication Title

Journal of Clinical Oncology

Recommended Citation

Lim, Sun Min; Tan, Jiunn-Liang; Dias, Josiane Mourao; Voon, Pei Jye; How, Soon Hin; Zhou, Xiangdong; Xiong, Hailin; Massuti, Bartomeu; Medley, Louise C.; Nagasaka, Misako; Vicente, David; Girard, Nicolas; Rittmeyer, Achim; Botesteanu, Dana-Adriana; Alhadab, Ali; Mahoney, Janine M.; Zhang, Jie; Bauml, Joshua Michael; Baig, Mahadi; and Scott, Susan Combs, "Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study." (2024). Research Publications (2021 to 2025). 5297.
https://knova.um.edu.my/research_publications_2021_2025/5297

Divisions

ummc

Funders

Janssen Research Development

Volume

42

Issue

17_SUP

Publisher

American Society of Clinical Oncology

Publisher Location

TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA